-
公开(公告)号:EP3851439A1
公开(公告)日:2021-07-21
申请号:EP19861061.0
申请日:2019-09-12
发明人: ZHANG, Yinsheng , XU, Hongjiang , REN, Jing , WANG, Qinglin , WU, Zheyang , JIN, Chao , SHI, Wei , WANG, Xiaojin , HE, Xiangyi , CHANG, Xiayun , WANG, Jie , ZHAO, Tianxiao
IPC分类号: C07D487/04 , A61K31/4985 , A61P19/02
摘要: The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.
-
2.
公开(公告)号:EP3915972A1
公开(公告)日:2021-12-01
申请号:EP19911146.9
申请日:2019-09-27
发明人: ZHANG, Yinsheng , AO, Wangwei , LI, Yuan , WANG, Hui , SHEN, Hangzhou , NI, Jie , ZHANG, Huan , WU, Jie , ZHANG, Li , CAO, Kai , LU, Peng , LIU, Xushi , WANG, Jie , ZHAO, Tianxiao , GE, Xingfeng , LU, Dandan , CHEN, Shuo , MA, Xueqin , SHI, Wei , WANG, Xiaojin , XU, Hongjiang
IPC分类号: C07D207/34 , A61K31/40 , A61P31/20
摘要: Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the medical uses thereof in treating diseases benefiting from the capsid protein assembly inhibitor, particularly diseases caused by hepatitis B virus infection.
-
公开(公告)号:EP3778569A1
公开(公告)日:2021-02-17
申请号:EP19777163.7
申请日:2019-03-29
发明人: ZHANG, Yinsheng , AO, Wangwei , LI, Yuan , WANG, Hui , SHEN, Hangzhou , NI, Jie , ZHANG, Huan , WU, Jie , ZHANG, Li , CAO, Kai , LU, Peng , LIU, Xushi , WANG, Jie , ZHAO, Tianxiao , GE, Xingfeng , LU, Dandan , CHEN, Shuo , MA, Xueqin , SHI, Wei , WANG, Xiaojin , XU, Hongjiang
IPC分类号: C07D207/34 , C07D405/12 , A61K31/4025 , A61P31/20
摘要: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.
-
-